Haemonetics Fair Value
HA
The fair market value of HAZ.F stock is 104.25 EUR. Relative to the market price of 83 EUR Haemonetics is undervalued by 25.4%
Eyestock's quantitative valuation approach is based on the method of estimating historical multipliers. To determine whether a stock is undervalued, we compare its current price to our estimated of fair value. The more undervalued a stock is, the more investment is profitable.
Fair Relative Value
Haemonetics Valuation
Current HAZ.F share ticker price is 83 EUR.
The fair value level of 104.25 EUR can be considered as an effective entry point for long-term investors to start investing in HAZ.F stock. For a more in-depth assessment, we provide a minimum value that can be used to increase a stock position and a maximum one that can be used to reduce it.
Price chart is not available
Current market price
Current price is 26% lower its fair value
Current price is 3% higher its minimum value
Current price is 107% lower its maximum value
Market price:
HAZ.F stock is undervalued
It means the current price may concern as a Moderate Risk Entry Point
Haemonetics Corp Stock Valuation Calculator
How do we value a stock?
As fair value, we use the product of the median Price-to-earnings ratios at the end of each reporting period for the last 5 years and earnings per share for the last 12 months. By analogy with the fair value, we calculate the maximum and minimum ones using the corresponding P/E extremums.
1
Maximum P/E over 5 years
74.55
2
Median P/E over 5 years
45.2
3
Minimum P/E over 5 years
34.86
4
Earning per share (last 12 months)
2.43 USD
Maximum value
1
x
4
=
171.95 EUR
Fair value
2
x
4
=
104.25 EUR
Minimum value
3
x
4
=
80.41 EUR
Haemonetics Corp price metrics
-5.62
Annual return (geometric mean)
44.67
Risk (standard deviation) of returns
β
1.46
Beta (volatility compared to market)